Enabling optimal antimicrobial use in East Africa

最近，人们越来越意识到对人类和动物健康的全球威胁，这是由于细菌，特别是细菌，对以前杀死它们的药物治疗没有反应，这种现象被称为抗菌素耐药性（AMR）。人们正在探索许多方法来改善这一问题，包括更好地使用抗生素的迫切需要。抗生素的最佳使用必须确保患有细菌感染的人继续获得他们所需的药物，细菌没有机会对这些“灵丹妙药”产生抗药性。我们在提高实验室能力方面进行了大量投资，这使我们能够检测和描述AMR，并通过监测网络向政府和国际机构报告这一问题。这些对实验室监测的投资尚未得到加强监测或改善抗生素使用（ABU）的干预措施的配合，特别是在低收入国家。我们建议将东非AMR领域的四项全球挑战研究基金（GCRF）投资合并为一个GCRF集群。我们将共同负责审查和“综合”我们所有的ABU研究结果，从东非的背景下，从整个人类和动物健康。我们将共同努力，共同设计“一个基本的信息包”，以优化东非环境下的ABU，并利用这一包来确定一种干预措施，以改变社区和卫生系统中的ABU行为。

Recently, there has been an increasing awareness of the global threat to human and animal health that is presented by the failure of germs, specifically bacteria, to respond to treatment with medicines which formerly killed them, a phenomenon known as Antimicrobial Resistance (AMR). Many approaches are being explored to ameliorate this problem, including the critical need to make better use of antibiotics. Optimal use of antibiotics must ensure both that people unwell with bacterial infections continue to have access to medicines that they need and bacteria do not have the opportunity to develop resistance to these "magic bullets". Huge investments have been made in improved laboratory capacity, which permits us to detect and describe AMR and report this problem through surveillance networks to governments and international agencies. These investments in laboratory surveillance have not been matched by enhanced surveillance of or interventions to improve antibiotic use (ABU), particularly in low income countries. We propose to bring together four Global Challenges Research Fund (GCRF) investments in the field of AMR in East Africa into a GCRF cluster. We will collectively take responsibility for reviewing and "synthesising" all of our ABU research findings from the East African context from across human and animal health. We will work together to co-design "an essential information package" to optimise ABU in the East African context and to define an intervention using this package to change ABU behaviours in communities and health systems.